Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-04
2007-12-04
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S550000
Reexamination Certificate
active
11024929
ABSTRACT:
This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (I). Each variable is defined in the specification
REFERENCES:
patent: 5856530 (1999-01-01), Webber et al.
patent: 5962487 (1999-10-01), Webber et al.
patent: 6214799 (2001-04-01), Webber et al.
patent: 6355807 (2002-03-01), Tian et al.
patent: 6362166 (2002-03-01), Webber et al.
patent: 6514997 (2003-02-01), Dragovich et al.
patent: 6531452 (2003-03-01), Dragovich et al.
patent: 6534530 (2003-03-01), Dragovich et al.
patent: 2001/0047006 (2001-11-01), Dragovich et al.
patent: 2002/0006943 (2002-01-01), Johnson, Jr. et al.
patent: WO 97/43305 (1997-11-01), None
patent: WO 9743305 (1997-11-01), None
patent: WO 9957135 (1999-11-01), None
Dragovich et al., J. Med. Chem., vol. 42, pp. 1213-1224 (1999).
Caulfield et al., “Parallel Solid-Phase Synthesis of Peptidyl Michael Acceptors”, J. Comb. Chem. 2:600-603, 2000.
Jenwitheesuk et al., “Identifying Inhibitors of the SARS Coronavirus Proteinase”, Bioorganic & Medicinal Chemistry Letters 13:3989-3992, 2003.
Dragovich et al., “Structure-Based Design of Irreversible, Tripeptidyl Human Rhinovirus 3C Protease Inhibitors Containing N-Methyl Amino Acids”, Bioorganic & Medicinal Chemistry Letters, 9 (1999) 2189-2194.
Dragovich et al., “Structure-Based Design of Ketone-Containing, Tripeptidyl Human Rhinovirus 3C Protease Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 10 (2000) 45-48.
Dragovich et al., “Solid-phase Synthesis of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 1: Optimization of Tripeptides Incorporating N-terminal Amides”, Bioorganic & Medicinal Chemistry 7 (1999) 589-598.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 7: Structure—Activity Studies of Bicyclic 2-Pyridone-Containing Peptidomimetics”, Bioorganic & Medicinal Chemistry Letters 12 (2002) 733-738.
Dragovich et al., “Synthesis of an Optically Active, Bicyclic 2-Pyridone Dipeptide Mimetic”, J. Org. Chem. 2002, 67,741-746.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure—Activity Studies”, J. Med. Chem. 1998, 41, 2806-2818.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure—Activity Studies”, J. Med. Chem. 1998, 41, 2819-2834.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure—Activity Studies of Ketomethylene-Containing Peptidomimetrics”, J. Med. Chem. 1999, 42, 1203-1212.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1Lactam Moieties as L-Glutamine Replacements”, J. Med. Chem. 1999, 42, 1213-1224.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure—Activity Studies of Orally Bioavailable, 2-Pydridone-Containing Peptidomimetics”, J. Med. Chem. 2002, 45, 1607-1623.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics”, J. Med. Chem. 2003, 46, 4572-4585.
Johnson et al., “Structure-Based Design of a Parallel Synthetic Array Directed Toward the Discovery of Irreversible Inhibitors of Human Rhinovirus 3C Protease”, J. Med. Chem. 2002, 45, 2016-2023.
Matthews et al., “Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes”, Proc. Natl. Acad. Sci USA, vol. 96, pp. 11000-11007, Sep. 1999.
Reich et al., “Substituted Benzamide Inhibitors of Human Rhinovirus 3C Protease: Structure-Based Design, Synthesis, and Biological Evaluation”, J. Med. Chem. 2000, 43, 1670-1683.
Tian et al., “An efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor AG7088 via asymmetric dianionic cyanomethylation of N-Boc-L-(+)-glutamic acid dimethyl ester”, Tetrahedron Letters, 42, 2001, 6807-6809.
Wang, “Design of rhinovirus protease inhibitors for the treatment of the common cold”, Drugs of the Future, 2000, 25(3):279-286.
Webber et al., “Design and Synthesis of Irreversible Depsipeptidyl Human Rhinovirus 3C Protease Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 11, 2001, 2683-2686.
Chen Wen-Chang
Kuo Chun-Wei
Liao Shao-Ying
Su Feng-Yih
Wang Ching-Cheng
Anderson Rebecca
Chung Susannah
Occhiuti Rohlicek & Tsao LLP
TaiGen Biotechnology
LandOfFree
Protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855057